Trv Gp V, Llc bought $11.7M of Septerna (SEPN)
Executed Oct 28 2024, disclosed Oct 28 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Oct 28 2024), the stock returned +8.1% (delay-adjusted); from the execution session (Oct 28 2024), +8.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Trv Gp V, Llc (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Septerna, Inc. (SEPN). Across 1 priced purchase filing, the average 21-session return was +8.1% from execution and +8.1% from disclosure (delay-adjusted; derived). The largest single filing was $11.7M of SEPN (650,000 sh across 2 lots, as filed), executed Oct 28 2024.
Healthcare · Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule produc…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→